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Nayla Jbeily  Introduction 
I- Introduction 
 
1. Sepsis: from Definition to Pathophysiology 
Sepsis is a life threatening disease and the leading cause of mortality in intensive 
care units worldwide (1). With a continuous rise in incidence, sepsis is a major health 
concern (2) retaining a significant and tremendous burden on the health care system 
registering an average annual cost of 16.7 billion US dollars back in 2008 (3). 
Although sepsis has been reported for over 2000 years, standardized clinical 
definitions are relatively recent but have been established for the systemic 
inflammatory response syndrome (SIRS) as well as the continuum of the sepsis 
syndrome from sepsis to severe sepsis and septic shock (3, 4). Sepsis itself is defined 
as the host’s innate and immunological response to an infection. An infectious 
etiology is required for the diagnosis of sepsis (5) and there has been a wide variety 
of identified infectious sources. Although bacteria remain the main source of infection 
with gram positive bacteria (namely Staphylococcus aureus) being the most 
commonly isolated in sepsis, fungal organisms (namely Candida spp.) have been 
increasingly reported (Figure 1.1) (3, 4). 
 
Figure 1.1: A representation of the most commonly isolated microorganisms in neonatal sepsis over 
three periods of time between the years 1980 and 2005. Staphylococcus aureus and Klebsiella 
pneumoniae, were the most commonly isolated gram(+) and gram(-) bacteria in sepsis between 1996 
and 2005. Candida spp. infections have been on the rise since 1996. Abbreviations: CONS- coagulase 
negative Staphylococci, GBS- Group B Streptococcus. The Figure is taken from Shim GH. et al. (2011) 
(6). 
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To this day, the pathophysiology of sepsis is not completely understood but is known 
to involve complex inflammatory and physiological processes. Following extensive 
research, the understanding of sepsis developed from the introduction of “wound 
putrefaction” by Hippocrates, the implication of fever in septicemia by Ibn Sina and 
the identification of bacterial presence decades later by Louis Pasteur to Hugo 
Schottmüller laying the groundwork of modern sepsis definitions (1914) by 
describing the presence of an infection as a fundamental component of the disease. 
Yet, it was the theory put through by Lewis Thomas that polarized and completely 
altered the understanding of the pathophysiology of sepsis by introducing the theory 
that it is the host response that drives the development of the syndrome (7, 8). The 
present concept was introduced into daily clinical practice by Roger Bone and 
colleagues who defined sepsis as “a systemic inflammatory response syndrome 
(SIRS) that can occur during infection” (7, 9). We now know that the host defense 
responses are initiated during tissue damage and microbial infections by pattern 
recognition receptors (PRRs) expressed on immune cells which recognize pathogen 
associated molecular patterns (PAMPs) and damage associated molecular patterns 
(DAMPs) expressed on microorganisms and damaged tissues respectively, 
subsequently initiating the immune response. A full-scale systemic immune activation 
leads to an overstimulation of the immune cells resulting in an imbalanced and 
overwhelming cytokine storm with a variety of cytokines, chemokines and 
complement factors which cause an excessive collateral damage involving different 
cell types and remote organs (7, 10). Additionally, the pro-inflammatory response 
induces the expression of secondary mediators such as reactive oxygen species 
(ROS) and bioactive lipids that further amplify the immune response (7, 11). In fact, 
several biological systems and cell types play a role in sepsis thus resulting in severe 
dysregulation of the inflammatory network. It is a syndrome with great heterogeneity 
that is also affected by a variety of premorbid factors as well as age and gender (7, 
12).  
Sepsis can be complicated through the development of organ failure namely severe 
sepsis followed by the development of septic shock with which mortality is radically 
increased (2) (Figure 1.2). It is associated with a haemostatic imbalance together 
with hypotension and compromised microcirculation resulting in impaired organ 
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perfusion. In fact, the microcirculatory status and the disturbances in microcirculation 
are key elements in the development of septic shock (13, 14). The liver plays a 
pivotal role in sepsis where hepatocyte cross-talk controls most of the inflammatory 
and coagulation processes. A continuous increase in cellular stress could result in 
liver dysfunction through compromised circulation and perfusion leading to an 
enhanced procoagulant and inflammatory process and eventually multiple organ 
failure (15, 16). 
 
or
or
(Organ Failure)
or
Figure 1.2: The disease continuum. Inflammation is the host's response to an infection or an insult. 
Normally, a local inflammatory response is usually resolved. However, if the inflammation becomes 
dysregulated, systemic activation of the innate immune system can occur. The complex clinical 
findings associated with this systemic activation are known as SIRS which is triggered by sterile 
inflammatory processes. SIRS presents with at least two of the following clinical findings: fever or 
hypothermia, tachycardia, tachypnea, or leucopoenia or leukocytosis. Sepsis is defined as a suspected 
or proven infection plus a SIRS. SIRS evolves to severe SIRS and sepsis to severe sepsis with the 
involvement of organ dysfunction (e.g., hypotension, oliguria, and thrombocytopenia). Severe sepsis 
is called septic shock when it is complicated by refractory hypotension. Analogously, severe SIRS 
(accompanied with organ dysfunction) can lead to shock. At each stage of the disease, recovery is 
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possible. However, the patient's survival chances decrease substantially in the later stages of the 
disease. The Figure is modified from Vanlaere I. et al. (2009) (17). 
2. Inflammation-triggered cytokine release 
Invading microorganisms trigger a cytokine mediated pro-inflammatory response 
resulting in the development of sepsis. This involves a combination of exaggerated 
inflammation and immune suppression. The latter, recently identified as 
compensatory anti-inflammatory response syndrome, is characterized by anti-
inflammatory mechanisms which are observed during the development of sepsis.  
Among the most widely addressed cytokines, TNF-α and IL-1 activate target cells 
which, once triggered, induce the generation of other cytokines (18). TNF-α 
dependent IL-6 is both a pro- and anti-inflammatory cytokine, which along with IL-8, 
IL-12, IL-10, interferon (INF)-γ and the granulocyte-colony stimulating factor (G-
CSF), plays a pivotal role in the regulation of the host response (18). Additionally, IL-
17 is a pro-inflammatory cytokine that has been recently implicated in the 
pathogenesis of sepsis through its ability to induce the generation of other 
inflammatory mediators such as IL-1b, IL-6 and TNF-α (19). Its inhibition in a murine 
sepsis model has resulted in the reduction of bacteremia and the systemic levels of 
cytokines associated with an improvement in survival (20). Other newly recognized 
cytokines include the macrophage migration inhibitory factor (MIF) and the pro-
inflammatory cytokine HMGB-1 which, when inhibited, have revealed an 
improvement in survival and protection against septic shock (21-24). However, these 
cytokines are not the sole triggers or drivers of SIRS and sepsis. In fact, therapeutic 
approaches based on a complete blockage of the inflammatory response have failed 
with respect to reducing mortality which highlights the complexity of sepsis (25, 26). 
 
3. Leukocyte recruitment during Host Response 
During inflammation and infection, a variety of cells are recruited to the site of 
inflammation including leukocytes, fibroblasts and endothelial and epithelial cells 
(27). Leukocyte recruitment involves a multi-step event cascade (Figure 1.3). 
Primarily, leukocytes migrate out of the blood circulation through the blood vessel 
wall. This process is initiated by tethering followed by leukocyte-endothelium 
interaction which begins with the rolling of white blood cells across the endothelium. 
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This mechanism is initiated through the expression of P and E selectins by the 
activated endothelium. Additionally, leukocytes express L-selectins thus resulting in 
optimal leukocyte-endothelium interaction (28). Rolling is followed by sticking or firm 
adhesion on the endothelium which involves integrins such as β2 and/or α4. 
Leukocyte integrins are activated by G-protein coupled receptors that are triggered 
through the latter interaction between the leukocytes and the endothelium with the 
help of chemokines (29). Activated integrins in turn firmly bind to endothelium 
ligands such as ICAM-1 and VCAM-1 resulting in firm adhesion. This adhesion is 
strengthened by signaling of chemokine receptors (30, 31).  
 
 
Figure 1.3: The classical neutrophil recruitment cascade. Initial tethering and rolling events are 
mediated by binding of endothelial selectins to neutrophil selectin-ligands. Subsequent engagement of 
chemokine receptors on rolling neutrophils activates integrins (LFA-1) leading to firm adhesion 
followed by crawling. Neutrophils then exit the microvasculature by transendothelial migration 
between endothelial cells or directly through endothelial cells. Once they reach the target tissues, 
neutrophils migrate to the site of infection guided by gradients of chemoattractants. The figure is 
taken from McDonald B. et al. (2011) (32). 
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Adhesion is followed by leukocyte crawling leading to emigration from the vessel into 
the tissue. Crawling is a process by which activated leukocytes move across the 
endothelium to the nearest endothelial junction, crucial for efficient emigration (33). 
Various proteins have been implicated with leukocyte emigration and include platelet 
endothelial cell adhesion molecule-1, CD99, junctional adhesion molecules and 
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vascular endothelial-cadherins (34). Following emigration into the tissues, leukocytes 
migrate to the site of infection guided by gradients of chemoattractants such as 
chemokines (primarily CXCR2 ligands for neutrophils), lipids (including LTB4, PAF) 
and complement anaphylotoxins (C5a and C3a) (32). 
Although the inflammatory response as well as leukocyte recruitment are crucial for 
fighting the infection, these events, especially the acute response of neutrophils, play 
also a substantial role in the pathology of sepsis-associated organ dysfunction (35). 
Once activated, emigrated leukocytes are sequestered in the capillary networks of 
organs such as the liver promoting organ dysfunction (27, 35-37) through 
hepatocellular damage or vascular hypoperfusion (15). 
 
4. Acid sphingomyelinase, Ceramide and Cellular stress response 
Sphingomyelin is a ubiquitous sphingolipid found in the nuclear envelope and 
intranuclear sites. Its role in cell signaling has become a major research focus with 
respect to its primary product ceramide, an emerging bioactive lipid and secondary 
messenger (38, 39). The breakdown of sphingomyelin to ceramide occurs through 
several pathways including the extracellular, stress-induced activation of acid 
sphingomyelinase (aSMase) that breaks down membrane bound sphingomyelin thus 
releasing ceramide (Figure 1.4) (39, 40). Acid sphingomyelinase was previously 
considered a “house-keeper” basically known for its role in Niemann Pick disease. 
However, we now understand that aSMase is triggered by a variety of stress stimuli 
and receptors including CD95, tumor necrosis factor receptors (TNFR), Toll-like 
receptor 4 (TLR4), CD5 as well as bacterial and viral infections thus shifting the 
attention over the past decade to the role of this enzyme in regulating ceramide 
generation and to the function of ceramide during host response (41, 42). The 
availability of the complete loss of function model with aSMase ko animals shed more 
light on the crucial role that this enzyme plays. These ko animals appear to be 
protected against a variety of stress stimuli such as radiation triggered cell death 
owed to impaired ceramide generation (43, 44). The upregulation of secreted 
aSMase was originally reported in an endothelial cell culture following cytokine-
triggered inflammation and was later reported in an animal model of endotoxemia 
(42). Acid sphingomyelinase has been purified from urine of patients with peritonitis 
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and was found to be elevated in these patients as compared to healthy controls (45). 
In 2005, plasma collected from critically ill patients revealed a continuous increase in 
levels of secreted aSMase with disease progression and severity from SIRS to sepsis, 
severe sepsis and multiple organ failure (46). With the increasing reports on the role 
of aSMase in response to infection, we now understand that once triggered, the 
enzyme is translocated to the outer leaflet of the plasma membrane resulting in a 
rapid and transient increase in ceramide generation which in turn accumulates 
forming ceramide-enriched membrane platforms also known as lipid rafts (Figure 
1.4) (42, 47). 
 
exoplasmatic layer
Signalintensity
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Figure 1.4: An exogenous stimulus triggers a pro-inflammatory stimulation resulting in the secretion 
of aSMase to the exoplasmatic layer. The enzyme breaks down sphingomyelin into ceramide which 
accumulates forming lipid rafts which develop into ceramide macrodomains. Receptors cluster and are 
activated in macrodomains resulting in an increase in signal intensity and triggering the cellular 
response. The Figure is taken from Hupe D., Dissertation, Jena University (2008). 
 
Ceramide and lipid rafts regulate the immune system either directly by signaling 
events or indirectly by affecting pro-inflammatory cytokine release, crucial in host 
response to infection. It has been shown that ceramide-mediated signaling is 
expressed by a variety of cells of the immune system (48, 49).  
Ceramide generation within rafts alters the biophysical properties of the membrane 
microdomains. In fact, ceramide tends to fuse small rafts forming ceramide-rich 
membrane platforms or macrodomains that serve as mediators for cell signaling. 
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These domains have been associated with clustering of receptor molecules, 
reorganization of signaling proteins and the exclusion of inhibitory signaling factors 
(47, 50). Once formed, they serve to cluster and signal CD95 and CD40 to name a 
few thus facilitating and amplifying signaling leading to cellular activation and 
ultimately apoptosis (50). Ceramide rich platforms recruit the TLR-4 complex which, 
when activated, plays a crucial role in the LPS response by macrophages (51). Also 
mediated by the raft modifications are the recruitment of FADD, caspase 5 and 
caspase 3 to aggregate CD95, crucial for apoptosis. Indeed, ceramide appears to be 
crucial for all three types of apoptosis; death receptors i.e. CD95, DR5 and TNF-
triggered apoptosis, non-receptor stimuli such as heat shock, toxins, H2O2 and 
microorganisms and finally deprivation of cells from growth factors (47, 52). 
Many receptors present outside rafts are also trapped in these macrodomains. The 
resulting high receptor density allows signal transmission to the cells. These signals 
could serve to recruit and/or exclude intracellular signaling proteins. Ceramide 
activates a variety of proteins that regulate cell transcription, proliferation and 
survival. Ion channels have also been identified as a target of ceramide enriched 
platforms which inhibit a potassium channel and a calcium channel both pivotal for 
the activation, differentiation, proliferation and regulation of apoptosis. However, it is 
still unclear how ceramide functions with respect to blocking these channels (47, 52). 
Additionally, various microorganisms utilize lipid rafts during infection whether it is 
for the internalization of bacteria in cases of Neisseria gonorrhea, for attachment of 
the pathogen in Pseudomonas aeruginosa infections or for the uptake of viruses such 
as rhinoviruses (47).  
 
5. Role of acid sphingomyelinase in Pathophysiology 
In cancer, a disease characterized by uncontrollable proliferation und compromised 
apoptosis, levels of ceramide appear to be significantly diminished especially in 
human colon cancers, gliomas and ovarian cancer. This suggested a downregulation 
of aSMase with subsequent reduction in ceramide generation thus inhibiting the 
apoptotic pathway. The aSMase pathway has also been associated with various 
antioncogenic treatments with the enzyme retaining a crucial secondary role in the 
action of these drugs. aSMase has also been linked to angiogenesis where aSMase ko 
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animals appear to be resistant to radiation therapy thus suggesting a crucial role of 
the enzyme in triggering irradiation-induced apoptosis (43, 44). 
Although aSMase appears to be beneficial in oncology, its role appears to be 
detrimental in chronic inflammation such as cardiovascular disease where a 
significant increase in the enzyme activity has been measured in patients with 
chronic heart failure (associated with cachexia and mortality) as well as in 
atherosclerosis where the enzyme is involved in the formation of atherosclerotic 
plaques (53). Diabetic patients, presenting with a higher risk of developing 
atherosclerosis, also registered elevated levels of plasma secreted aSMase. The 
enzyme has also been associated with insulin resistance through negative modulation 
of the insulin receptor substrate (IRS-1) by ceramide (43, 54-56).  
Acid sphingomyelinase is crucial for maintaining a normal brain function as suggested 
by the neurodegenerative disorder in patients with Niemann Pick disease, yet altered 
levels of the enzyme have been associated with depression, Alzheimer’s disease and 
ischemia. Higher aSMase activity and ceramide levels have been registered in 
patients with major depression as well as Alzheimer’s disease. Additionally, in a 
mouse model of cerebral ischemia, wt animals revealed elevated aSMase activity as 
well as ceramide and cytokine levels that were not observed in aSMase ko mice 
which reflected a better outcome in the latter animals (43, 57). 
A role of aSMase in pulmonary disease has been reported in emphysema and cystic 
fibrosis, to name a few. A registered elevation in ceramide levels has been reported 
in patients suffering from emphysema. According to Petrache et al., ceramide retains 
a crucial role through the activation of receptors ultimately leading to alveolar cell 
apoptosis and alveolar destruction, crucial in the pathogenesis of emphysema. In 
cystic fibrosis, a role of aSMase with respect to bacterial spread and persistence has 
been elucidated. In fact, aSMase ko animals or those treated with a pharmacological 
inhibitor of the enzyme appear to be more resistance to Pseudomonas aeruginosa 
infections with a decrease in the baseline of pulmonary inflammation (43, 58). 
As previously mentioned, aSMase and ceramide also play a complex and crucial role 
in infection with respect to microorganism internalization and survival yet these 
processes, especially in sepsis, are not entirely understood. However, aSMase activity 
is reportedly elevated in endotoxemia reaching a 2 to 2.5 fold increase (43, 59). 
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6. Inhibitors of the acid sphingomyelinase enzyme 
Although potent and selective inhibitors of aSMase have been identified, they present 
with major limitations and disadvantages with respect to toxicity, stability and cell 
penetration (60). On the other hand, desipramine and imipramine, well-established 
drugs for the treatment of major depression, were later found to be functional 
inhibitors of acid sphingomyelinase (FIASMAs) and appeared to efficiently reduce the 
levels of aSMase with no cytotoxic side effects (60, 61). They function by detaching 
the aSMase enzyme from the inner lysosomal membranes resulting in its deactivation 
and degradation (Figure 1.5). It is therefore a non-specific inhibitor requiring high 
lysosmal concentrations which are reached by lysosomal trapping due to 
physicochemical properties. 
 
 
Figure 1.5: Drug-induced functional inhibition of aSMase is the result of lysosomal accumulation and 
detachment of aSMase from the inner lysosomal membrane. The figure shows a schematic model of 
how FIASMAs (functional inhibitors of acid sphingomyelinase) and other lipophilic weak bases cumulate 
intra-lysosomally, thereby functionally inhibiting aSMase. A low lysosomal pH is maintained by an ATP-
driven proton pump. (1) Weak bases (B) cumulate in intracellular acidic compartments because the 
lysosomal membrane is much less permeable to the charged protonated bases (BH+) compared to the 
uncharged form. The enzyme aSMase is attached by electrostatic forces to the inner lysosomal 
membrane, thereby being protected against proteolysis. (2) High concentrations of the protonated 
bases disturb the binding of aSMase to the inner lysosomal membrane and result in detachment of 
aSMase (3) and subsequent inactivation (4), possibly involving proteolysis [89]. The figure is taken from 
Kornhuber J. et al. (2008) (62). 
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Most of the available FIASMAs possess appropriate ADME properties (Absorption, 
Distribution, Metabolism and Excretion). Although they have variable lyososmal uptake 
characteristics, desipramine is a FIASMA with a fast uptake kinetic as well as a 
moderate lysosomal accumulation. These inhibitors are also capable of extensively 
binding to the tissue due to their special physicochemical properties, i.e. weak basicity 
and high lipophilicity (63, 64). It is important to note however, that FIASMAs do not 
result in a complete inhibition of the enzyme but rather retain a residual aSMase 
activity thus avoiding the accumulation of sphingomyelin and the development of 
Niemann-Pick disease. Additionally, pharmacological inhibition of the enzyme is 
reversible as levels of aSMase return to control values three days following the drug 
withdrawal (57, 65). 
As inhibitors of aSMase with a resulting attenuated receptor-induced apoptosis, 
FIASMAs present with a possible broad clinical application for the treatment of 
common diseases (66). Their anti-apoptotic and neuroprotective effects are promising 
for the treatment of neurological disorders such as Parkinson’s disease, multiple 
sclerosis, brain stroke and ischemia (61, 67, 68). FIASMAs are also promising for the 
treatment of liver disease and anemia in Wilson’s disease (69), inflammatory bowel 
disease (70), atherosclerosis and heart disease (43) as well as cystic fibrosis (65, 71). 
Ceramide plays a key role in acute and chronic lung disease which could be alleviated 
with the use of these aSMase inhibitors (58, 72). FIASMAs are used for treatment of 
major depression which has been associated with diminished aSMase activity (57). 
Preliminary results using the endotoxemia model also suggest a possible advantage for 
the use of FIASMAs in infection and sepsis (46, 73). 
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7. Aim of the Project  
Here we elucidate the role of aSMase in the acute phase of sepsis using the peritonitis 
sepsis model. We aimed to define and establish the peritoneal contamination and 
infection (PCI) model with respect to reproducibility, reliability and transferability to the 
clinical setting and with respect to course by measuring various parameters of host 
response including systemic cytokines, bacterial burden and markers of organ 
(dys)function. Liver dysfunction and changes in microcirculation and leukocyte-
endothelium interaction were additionally evaluated by intravital microscopy. A 
complete set of experiments was also performed comparing PCI to another commonly 
used animal model of systemic inflammation, the endotoxemia shock model.  
To elucidate the role of aSMase in sepsis, I compared the complete loss of function 
model to wt littermates and wt animals pretreated with a pharmacological inhibitor, 
desipramine. I stratified the role of the enzyme in host response through the analysis 
of established parameters of host response such as bacterial burden, cytokines, 
leukocyte and platelet counts, markers of organ (dys)function and ROS release. I also 
stratified the leukocyte phenotype by intravital microscopy, gene expression and 
analysis of surface protein expression. Additionally, I analyzed the effect of aSMase 
activity and its role with respect to outcome by performing a survival analysis. I also 
investigated the possible beneficial role of the functional inhibitor desipramine in 
ameliorating the host response to sepsis addressing its possible use in the treatment of 
the host response. 
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II- Manuscripts 
 
Manuscript 1: Gonnert et al. (2011). Journal of Surgical Research. 
 
Characteristics of clinical sepsis reflected in a reliable and reproducible 
rodent sepsis model. 
 
Summary: 
For the purpose of mimicking the clinical situation of diffuse peritonitis in a reliable 
murine sepsis model, we aimed to establish a standardized and reproducible model, 
PCI or peritoneal contamination and infection to be utilized in the present project. 
This method has the advantages of simplicity and limited variability in outcome as 
compared to other commonly used sepsis models. Briefly, we collected human stool 
samples from healthy non-vegetarian donors. Following microbiological analysis and 
stool preparation and preservation, a standardized dilution of fecal slurry was 
injected intra-peritoneally (IP) to mimic diffuse peritonitis sepsis in humans. In order 
to characterize the model, we performed several experiments including the 
measurement of cytokines, blood counts, blood gas analyses and markers of organ 
(dys)function as well as several trials of survival analysis to confirm reproducibility. 
The summation of results clearly indicated an infectious focus and the development 
of diffuse peritonitis. Laboratory findings were very similar to the clinical course of 
patients with sepsis. Results support the standardization and reproducibility of the 
PCI method associated with various prototypical features of sepsis and multi-organ 
failure. 
 
Reference: Gonnert FA, Recknagel P, Seidel M, Jbeily N, Dahlke K, Bockmeyer CL, 
Winning J, Lösche W, Claus RA, Bauer M. (2011). Characteristics of clinical sepsis 
reflected in a reliable and reproducible rodent sepsis model. J Surg Res. 170:e123-
34. 
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Author’s Contribution: 
To complete the picture with respect to organ involvement during host response, I 
performed intravital microscopy of the liver using an epifluorescent microscope to 
evaluate changes in leukocyte-endothelium interaction, highlighted by rolling and 
sticking. I also evaluated changes in liver microcirculation and perfusion. Following 
the experiments, I analyzed the videos and images and assisted in preparing the 
related figures for the manuscript. I also assisted with the literature and discussion 
with respect to microbiology analysis and survival of microorganisms as well as 
revision of the manuscript before submission.  
 
Signature ----------------------- 
             Dr. Ralf Claus 
 
 
Evaluation of hepatic microcirculation. Intravital microscopy (IVM) of the liver was performed in 
four animals per group. (A) Microcirculation was analyzed at 5 and 15 h post-insult. The average 
percentage of (non-)perfused sinusoids is indicated. The inset depicts the quality of flow that was 
determined in perfused sinusoids at 5 and 15 h. (B) Leukocyte-endothelium interaction was analyzed 
in post-sinusoidal venules 15 h post-insult. Adherent leukocytes that did move or detach from the 
endothelium prior to a period of 30-s were defined as ‘rollers’. Those that adhered to the endothelial 
wall for longer were classified as ‘stickers’. The number of rollers and stickers were calculated per 
mm2 of endothelial surface (ES). (C) Rolling and sticking of in-vivo stained leukocytes demonstrated 
in representative overlays of 30-second video sequences. Data is given as mean ± SEM, *<0.05 
versus sham, **<0.05 versus sepsis 5 hours. 
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Manuscript 2: Recknagel et al. (2013) Liver International. 
 
Mechanisms and functional consequences of liver failure substantially 
differ between endotoxemia and fecal peritonitis in rats. 
 
Summary: 
The endotoxemia shock model is frequently used to describe and understand the 
pathophysiology and mechanisms of the host response to sepsis. As part of 
establishing PCI as an efficient yet more clinically relevant model in mimicking the 
human situation with respect to sepsis and severe sepsis, we compared physiological 
and inflammatory changes in both polymicrobial peritonitis and endotoxemia. Both 
models induced the host response but interestingly so in a different way. Although 
both models resulted in a similar morbidity, the PCI model induced a more visible 
hepatic dysfunction with a significant increase in markers of cholestasis (serum 
bilirubin) as seen in clinical practice. Unlike PCI, LPS injection did not show signs of 
severe peritonitis but rather cell toxicity and death resulting from endotoxemia and 
shock. Our results display PCI as a reliable and clinically relevant sepsis model 
resulting in a more adaptive cellular response that is more physiologically and 
clinically relevant than endotoxemia.  
 
Reference: Recknagel P, Gonnert FA, Halilbasic E, Gajda M, Jbeily N, Lupp A, 
Rubio I, Claus RA, Kortgen A, Trauner M, Singer M, Bauer M. (2013). Mechanisms 
and functional consequences of liver failure substantially differ between endotoxemia 
and fecal peritonitis in rats. Liver Int. 33:283-93. 
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Author’s Contribution: 
To observe changes in leukocyte-endothelium interaction occurring in the liver, the 
addition of intravital microscopy was a valuable tool with which to assess these 
changes in post-sinusoidal venules and sinusoids comparing both models. As such, I 
performed intravital microscopy experiments of the liver using an epifluorescent 
microscope. At the end of the experiments, I analyzed the videos and images to 
generate the data which was represented in box plots and I prepared representative 
illustrations reflecting the results. I also assisted in animals handling and surgery. 
Finally, I assisted in the revision of the manuscript before submission. 
 
Signature:------------------------ 
   Dr. Ralf Claus 
 
Leukocyte recruitment. Leukocyte-endothelium interaction in post-sinusoidal venules was analysed 
in-vivo by intravital microscopy 5 h' post-insult. Indicated are the (B) ‘roller’ count and (C) ‘sticker’ 
count per mm2 endothelial surface (per 100 leucocytes; *<0.05 vs. sham). (A) depicts representative 
overlays of 30 sec movies of post-sinusoidal venules with corresponding sinusoids taken 5 h post-
insult in sham-, PCI- and LPS (30 mg/kg BW)-treated animals respectively (original magnification 
400×, n = 3 animals per group, five ROI per animal). White arrows indicate leucocytes that moved or 
detached from the endothelium within 30 s (‘rollers’), grey arrows indicate leucocytes that adhered to 
the endothelial wall for >30 s (‘stickers’). 
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Manuscript 3: Jbeily et al. (2013). Journal of Lipid Research 
 
Hyperresponsiveness of mice deficient in plasma-secreted 
sphingomyelinase reveals its pivotal role in early phase of host response. 
 
Summary: 
To investigate the role of aSMase in sepsis, we performed a set of experiments with 
the loss of function model (aSMase ko animals) compared to wt littermates using the 
PCI sepsis model. Since the increase in aSMase activity and the subsequent rapid 
and transient ceramide generation has been associated with an unfavorable 
outcome, we expected to observe an improvement in outcome (survival) with 
aSMase ko animals subjected to sepsis. Primarily, analysis of bacterial burden in 
different organs revealed a significantly elevated CFU in both wt and ko animals. 
Strikingly however, both genotypes presented with a similar survival (20% after 72 
hours) but our data strongly suggested a different pathway between the two 
genotypes. In wt animals, the insult resulted in an increase in aSMase activity leading 
to rapid and transient formation of ceramide resulting in detrimental effects in the 
late phase of sepsis with subsequent high mortality. Although we expected a better 
result with respect to survival and overall outcome with the abrogation of aSMase 
activity, we rather highlighted a dual role of the enzyme with its beneficial role in the 
early phase of sepsis with respect to bacterial elimination. Therefore, the complete 
abrogation of aSMase in the ko animals proved to be detrimental resulting in a 
hyperresponsive state and an outcome similar to wt littermates through different 
pathways.  
 
Reference: Jbeily N, Suckert I, Gonnert FA, Acht B, Bockmeyer CL, Grossmann SD, 
Blaess MF, Lueth A, Deigner HP, Bauer M, Claus RA (2013). Hyperresponsiveness of 
mice deficient in plasma-secreted sphingomyelinase reveals its pivotal role in early 
phase of host response. J Lipid Res., 54:410-24. 
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Author’s Contribution: 
As the first author in this manuscript, I performed the experiments with the 
exception of the determination of phagocytotic activity, cytokine profiles (Iris 
Suckert), ROS generation (I supervised Sascha Grossmann) and gene expression 
(microarray). The experiments I performed included animals handling and surgery, 
sepsis induction, determination of bacterial burden (with the assistance of Iris 
Suckert), survival analysis, blood analysis for complete blood counts, leukocyte 
subpopulations and measurement of markers of organ (dys)function, histology 
studies for assessment of granulocyte migration (with the assistance of Iris Suckert), 
expression of surface markers of leukocytes by flow cytometry (while supervising 
Sascha Grossmann), measurement of aSMase activity in the plasma, isolation and 
preanalytics of leukocytes for ceramide measurements (ceramide measurements 
were performed by Anja Lüth in Potsdam) and intravital microscopy of the liver. I 
also assisted in real-time PCR experiments. 
Finally, I generated all figures and prepared the manuscript. The final draft was 
revised by Dr. Ralf Claus and proofed by all co-authors. 
 
Signature:----------------------------- 
       Dr. Ralf Claus 
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Manuscript 4: Jbeily et al. (2013). Disease Models and Mechanisms 
 
Identification of a distinctive Leukocyte-Phenotype following 
pharmacological inhibition of aSMase during Host Response 
 
Summary: 
Sepsis is characterized by an overwhelming host response with limited treatment 
options. The results obtained with the use of the ko model urged us to apply a 
pharmacological inhibition of the enzyme using desipramine which does not 
completely abrogate the function of the aSMase enzyme and has shown to be 
promising in treatment of common diseases. We addressed the potential of 
desipramine, a functional inhibitor of aSMase, for regulating the host response. 
Indeed, we identified a distinctive leukocyte phenotype in animals pretreated with 
desipramine compared to vehicle-treated animals. The former animals presented 
with different gene expression profiles (1) resulting in alleviated cytokine levels in the 
late stage of sepsis and (2) abrogating the increase in ROS production in the early 
phase. The use of this inhibitor also resulted in an altered surface protein expression 
thus revealing a missing increase in leukocyte-endothelium interaction in the liver 
following sepsis induction. As a consequence, we observed alleviated liver 
dysfunction as measured by laboratory markers of organ dysfunction and an 
improved survival with desipramine pretreatment (42%) as compared to vehicle 
(20%). 
 
Reference: Nayla Jbeily, Sascha D. Grossmann, Iris Suckert, Falk A. Gonnert, 
Tobias Ludwig, Anja Lueth, Burkhart Kleuser, Jürgen Rödel, Michael Bauer, and Ralf 
A. Claus (2013). Identification of a distinctive Leukocyte-Phenotype following 
pharmacological inhibition of aSMase during Host Response (Submitted for review 
in Dis Model Mech.) 
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Author’s Contribution: 
As the first author of the manuscript, I performed the experiments with the 
exception of the determination of phagocytosis activity, cytokine profiles (Iris 
Suckert) and ROS generation (I supervised Sascha Grossmann). The experiments 
included sepsis induction (PCI) and treatment of animals with desipramine for 
pharmacological inhibition of aSMase, survival analysis, determination of bacterial 
burden (while supervising Tobias Ludwig), blood analysis with complete blood counts 
and analysis of leukocyte populations, measurements of markers of organ 
(dys)function, histology studies for the assessment of granulocyte migration, surface 
protein expression on leukocytes by flow cytometry, measurement of aSMase activity 
in the plasma, isolation of leukocytes and preanalytics for ceramide measurements 
(performed by Anja Lüth), gene expression by qPCR (while assisting and supervising 
Sascha Grossmann) and intravital microscopy. 
Finally, I generated all figures and prepared the manuscript. The final draft was 
revised by Dr. Ralf Claus and proofed by all co-authors. 
 
 
 
Signature:--------------------- 
           Dr. Ralf Claus 
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Manuscript 5: Jbeily et al. 
Comparison of Carboxyfluorescein diacetate succinmidyl ester (CFSE) and 
Rhodamine 6G for in-vivo labeling of leukocytes [In Preparation]. 
 
Summary: 
Intravital microscopy is an excellent tool for monitoring changes in the liver, an 
organ retaining a crucial role during the development of sepsis. Although Rhodamine 
6G is currently the most commonly used dye for monitoring changes in leukocyte-
endothelium interaction and microcirculation, we compare it to CFDA-SE with respect 
to efficiency of leukocyte labeling in intravital microscopy. The latter dye shows more 
specificity in labeling thus resulting in clearer imaging which is challenging with the 
use of Rhodamine 6G (absorbed by the background). Therefore, we propose the use 
of CFDA-SE, a better choice for leukocyte labeling in intravital microcopy. 
 
 
Author’s Contribution: 
As a first author, I performed the experiments: (1) intravital microscopy of the liver 
using an epifluorescent microscope. Following animal preparation and 
catheterization, I performed imaging using the two dyes followed by video image 
analysis. I later analyzed the videos for leukocyte-endothelium interaction and 
prepared the graphs and representative images for the manuscript. (2) I also 
performed flow cytometry experiments to assess the ability of each dye to label 
different leukocyte subpopulations.  
Finally, I generated all figures and prepared the first draft. 
 
 
Signature: ---------------------------- 
        Dr. Ralf Claus 
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III- Discussion 
 
1. The Burden of the Disease 
As a research group focusing on and addressing a wide spectrum of the sepsis 
continuum, our combined efforts are to try to understand its complexity. Over the 
past few decades, researchers around the world have witnessed great inventions and 
developments in modern medicine that improved the quality of health care and 
extended the average life span. Yet, despite huge efforts, we still find ambiguities in 
several aspects of the medical field that require our attention (74-76). Although 
science, research and medicine have given us great insight into the complexity of 
sepsis, the worldwide incidence, morbidity and mortality rates due to sepsis are still 
on the rise and the treatment has become more challenging (77-79). Recent reports 
have registered a 9% increase in sepsis-related mortality rate per year in the US 
since the year 2000 (77). A 28.6% mortality rate was reported in the US following 
the evaluation of six million hospital records in seven states and 751,000 cases of 
sepsis (80). The average mortality rate due to sepsis in Brazil is stated to be around 
29% (81). Mortality due to sepsis increases with the complication of severe sepsis 
where the UK for example recently reported a 35% mortality rate (82). In fact, with 
sepsis claiming the life of 20,000 people per day worldwide and with 1.8 million 
cases reported annually, the European Union alone has reported 90.4 cases of severe 
sepsis per 100,000 population (82), and sepsis research is therefore on a drive. 
Today, there is a huge effort built into research to address the challenges of sepsis in 
the hope of compiling a more complete picture of the pathophysiology of the host 
response to infection thereby evolving more suitable, efficient and successful 
therapeutic options. Although in-vitro experiments with tissue cultures have been of 
great value, they are limited with respect to clinical relevance and transferability 
(83). For this purpose, various animal models of sepsis have been developed with 
the goal of mimicking the human condition thus giving a more in-depth insight into 
the clinical situation. Established animal models include intra-peritoneal (IP) injection 
of LPS or bacterial dilutions and cecal ligation and puncture (CLP), both of which 
present with advantages as well as limitations (84). 
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2. Added value of the PCI model for sepsis research 
As part of the present project, we aimed to standardize and characterize the PCI 
model to be utilized by our research group as well as in the present experimental 
setup addressing the role of aSMase in sepsis. This model is clinically relevant as 
sepsis is triggered by a polymicrobial intra-abdominal infection that closely reflects 
the clinical situation observed in 50% of patients admitted to the ICU due to sepsis, 
severe sepsis and septic shock (85, 86). It is a simple method comprising an IP 
injection of a standardized and characterized dilution of fecal slurry. Microbiological 
analysis was performed following the collection of human faeces from healthy non-
vegetarian donors which revealed the presence of a mixture of aerobic and anaerobic 
microorganisms that are frequently isolated in intra-abdominal infections such as E. 
coli and Bacteroids (87). An intra-peritoneal injection of a standardized stool 
suspension results in a diffuse peritonitis characterized by an overwhelming infection 
and paralleled with a systemic inflammatory response thus resulting in the clinical 
manifestations of sepsis. We measured a significant increase in bacterial burden 
following sepsis induction in organs and blood indicating a wide spread of the 
infectious focus accompanied by a significant increase in systemic cytokine levels. We 
were also able to observe involvement of remote organs as demonstrated by the 
increase in various laboratory markers of organ (dys)function following PCI. For 
example, we observed an early increase in markers of hepatocellular (dys)function 
and cholestasis as well as microcirculatory changes and enhanced leukocyte-
endothelium interaction reflecting the development of liver dysfunction (87).  
As reproducibility is a critical requirement for the reliability of a sepsis model, we 
repeated survival experiments over a period of 16 months using a frozen stool batch 
which confirmed the reproducibility of PCI (87). 
 
3. Translational aspects of the PCI model 
The measured parameters of host response and the reproduced experiments proved 
PCI as a reliable and clinically relevant model mimicking the clinical condition of 
diffuse peritonitis. Recently, a paper by Seok J. et al. addressed the reliability of 
different murine models of inflammation, including CLP- and endotoxemia, by 
comparing the genomic response in these models with the corresponding human 
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inflammatory diseases. With respect to the endotoxemia shock model, the authors 
concluded that this model is unreliable and poorly mimics the clinical situation (88). 
Unlike PCI, the endotoxemia model is based on the injection of LPS, a prototypic pro-
inflammatory mediator from gram negative bacteria, which leads to a strong yet 
short lived immune response (89). In fact and as part of our objective to characterize 
and standardize the PCI model, we performed a set of experiments comparing 
polymicrobial intra-abdominal infections (fulfilled by PCI) to the endotoxemia shock 
model (LPS injection). We were able to demonstrate that where the PCI model 
induces a more visible hepatic dysfunction with a significant increase in markers of 
cholestasis (serum bilirubin) as seen in clinical practice, the LPS model did not show 
any signs of severe peritonitis but rather cell toxicity and death resulting from 
endotoxemia and shock (90). Also addressing other models such as CLP, Seok J. et 
al. concluded that all animal models are unreliable and poorly mimic the clinical 
situation. On the other hand, Lambeck et al. underlined the translational aspects of 
PCI through a comparison of gene expression in blood samples collected from murine 
animals following PCI and those collected from the pediatric ICU. The authors found 
significantly overlapping data in differentially expressed genes and could validate the 
reproducibility of PCI (91). Therefore, it is safe to suggest that the general 
conclusion reached by Seok J. et al. is not completely reliable and was unfairly 
generalized with respect to all animal sepsis models without sufficient supporting 
scientific grounds. 
The widely and commonly used CLP sepsis model is one that is rather characterized 
by abscess formation which could contain the infection thus presenting with low-
grade inflammation as opposed to diffuse peritonitis with subsequent sepsis (87, 92). 
Additionally, a constant leakage of faecal content cannot be guaranteed and the CLP 
procedure presents with limitations with respect to the standardization of the number 
of punctures as well as the manual extrusion of cecal contents (84, 93), namely 
operator inconsistency. This pitfall is resolved with the PCI model that does not 
require surgery. Moreover, the simple intra-peritoneal injection of the standardized 
stool dilution results in low variability (87). It could however be interesting and of 
great value to perform an additional set of experiments comparing the CLP and PCI 
models. 
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4. Long-term sequelae of sepsis 
As shown by a recent report from our group, the PCI sepsis model also has long-
term sequelae for surviving animals. In the post-acute phase, i.e. 28 days after 
sepsis induction, animals presented with abscess formation, liver fibrosis, elevated 
leukocyte counts and markers of liver (dys)function (94). Preliminary results of our 
group also include positive blood and tissue cultures 28 days following the septic 
insult with the use of antibiotics (for three days) which strengthens the transferability 
of this model  This is in line with Otto et al. reported positive blood cultures in septic 
patients following diagnosis and antibiotic administration (Figure 6) with Candida 
spp. increasingly reported (30%) in the later phase of sepsis (95). Therefore the 
model seems to adequately reflect the clinical situation with respect to long-term 
sequelae of sepsis and as such, further research using this model is suggested for an 
in-depth understanding of the mechanisms in the post-acute phase of sepsis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Distribution of non survivors and positive blood cultures during sepsis. Relative numbers 
of deaths per day from 999 patients with severe sepsis or septic shock according to ACCP/SCCM 
criteria are shown from the day of onset/diagnosis until observation Day 36. Three phases were 
defined, characterized by the nadir at Day 5 and Day 15. Also, the average rates of positive blood 
cultures without CNS in a five-day period with respect to sampling times are shown. Abbreviations: bc, 
blood cultures; CNS, Coagulase negative staphylococci; #, numbers; %, relative number. The Figure 
is taken from Otto GP. et al. (2011) (95). 
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5. Regulation of the Host Response by acid sphingomyelinase 
As a key modulator of cell signaling, the roles of ceramide and aSMase in the 
pathology of common diseases have become a major research focus. Levels of 
aSMase were shown to significantly increase with disease progression from SIRS to 
severe sepsis and shock (46). Additionally, an upregulation in levels of secreted 
aSMase has been reported in chronic inflammation such as chronic heart failure (53). 
We therefore used the PCI model to address and characterize the role of aSMase in 
sepsis. This was possible with the availability of the loss of function model which 
allowed us to elucidate the role of aSMase in sepsis by comparing ko animals to wt 
littermates. This animal model used in the present study is a well characterized, 
highly reproducible and reliable animal model. It is commonly used to study the role 
of aSMase in a variety of common diseases such as cystic fibrosis (47, 48, 96). 
Primarily, the differences between the two genotypes were elucidated by the 
measurement of aSMase activity in the plasma and in leukocyte lysates as well as the 
levels of ceramide in circulating leukocytes at baseline as well as early sepsis. 
Following sepsis induction, the immune system is activated through a variety of 
stimuli and events, corner stones to for the development of sepsis. The presence of 
microorganisms creating an infectious focus results in the activation of the aSMase 
enzyme leading to the generation of ceramide from sphingomyelin (46). Indeed we 
measured a significant, sepsis-triggered increase in secreted aSMase in the plasma of 
wt animals also paralleled with a significant decrease in aSMase activity in a 
leukocyte lysate. As expected, aSMase activity in ko animals was negligible at 
baseline as well as following sepsis induction. This method is based on the hydrolysis 
of fluorescently labeled sphingomyelin which presents with sensitivity to light and 
therefore could, under false conditions, affect the results. This was however averted 
by the use of best-practice methods and by performing the experiment and 
subsequent analysis in the dark. Also, it is important to note that the results of 
aSMase activity measurements using fluorescently labeled sphingomyelin were 
similar to the use of radioactive-labeled sphingomyelin (46, 97). Additionally, 
maintaining a pH of 5.5 allowed the safeguarding of the enzyme and its products. 
Moreover, the levels of the intermediate product ceramide in circulating leukocytes 
were determined by an additional method independently (Mass spectroscopy) 
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through a collaboration with experts in the field. However, ceramide levels at 
baseline were significantly higher in ko animals compared to wt littermates. Resulting 
from an unknown compensatory mechanism (98), these ceramide levels at baseline 
(as well as after sepsis induction) are sufficient to maintain a normal function at a 
healthy state but not under septic conditions. The missing increase of ceramide in ko 
animals after sepsis induction outlines the pivotal role of this enzyme in the rapid and 
transient formation of ceramide.  
Measuring the ceramide levels in circulating leukocytes required the isolation of these 
leukocytes from whole blood prior to analysis. This presented with challenges and 
limitations. The isolation procedure could per se result in the activation of the cells 
thus altering ceramide levels and resulting in false positive results. To overcome this 
challenge, we used the highly effective agent diisopropylfluorophosphate (DFP) 
which acts as a broad spectrum enzyme inhibitor preventing the activation of 
hydrolyzing enzymes during the isolation process. Another limitation was the loss of 
leukocytes due to the isolation procedure. In fact, cells might be lost or destroyed in 
the process of isolation. The analysis method however required at least one million 
cells per samples which urged us to pool leukocytes from several animals per group 
to achieve this goal. Therefore animal to animal deviations could not be observed in 
this experiment. 
As the measured increase in aSMase activity in wt animals triggers a cellular stress 
response in the early phase which, in an overwhelming fashion, could act as a trigger 
of tissue damage in the late phase of the host response (73), we expected an 
improvement in outcome in ko animals due to the absence of continuous, rapid and 
transient ceramide generation. Surprisingly, survival in ko animals was similar to wt 
animals (20%). In subsequent experiments analyzing various parameters of the host 
response, we identified a different pathway in the ko animals that lead to a similar 
survival but highlighted a dual role of aSMase in sepsis. In wt animals, a complete 
set of data, with the continuous increase in systemic cytokines, ROS generation, 
leukocyte-endothelium interaction and markers of organ (dys)function, along with 
the measured increase in aSMase activity and ceramide levels following sepsis 
induction, led us to speculate that this increase could be the course or the 
consequence resulting in tissue damage, the development of organ failure and high 
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mortality in the late phase of host response. Thus, the increase in enzyme activity, 
leading to rapid and transient ceramide formation, appears to have a detrimental 
outcome. Surprisingly, the complete loss of aSMase triggered a hyperresponsive 
state ultimately implicating a pivotal role of the enzyme in the early phase of host 
response to sepsis. The completely abrogated aSMase activity resulted in a high 
mortality similar to wt, only through a different pathway. This was primarily 
highlighted with the analysis of the bacterial burden in blood and tissue where ko 
animals registered a significantly higher CFU in blood and liver following the septic 
insult as compared to wt. In fact, ceramide, produced actively by secreted aSMase, 
plays a pivotal role in elimination of microorganisms through the activation of the 
innate immune response (99). The absence of the enzyme, according to Ching et al., 
left murine animals more susceptible to Sindbis virus-induced fatal encephalomyelitis 
(100). This phenomenon has also been observed in aSMase ko animals subjected to 
acute pulmonary infection with Pseudomonas aeruginosa. These animals, unlike wt, 
were unable to successfully eliminate the microorganisms from the lung and 
ultimately succumbed to sepsis a few days later (96). Therefore, the present data 
obtained with the analysis of the bacterial burden suggested that the aSMase 
enzyme retains a pivotal role in the early phase of host response with respect to 
bacterial elimination. 
Although aSMase ko animals registered a significantly higher bacterial burden, the 
phagocytotic ability was intact as ko animals even registered a more pronounced 
increase in phagocytotic activity following the septic insult as compared to wt. 
According to Utermohlen et al., the absence of the aSMase enzyme does not affect 
the uptake of the bacteria by phagocytes but rather results in a defective intracellular 
elimination (101). The overwhelming infection triggered a more pronounced 
response by leukocytes leading to a more significant increase in phagocytosis that 
was however inefficient. The present data suggested the inability of granulocytes to 
eradicate phagocytosed microorganisms possibly due to impairment in effector 
mechanisms (101).   
The high bacterial burden in turn triggered an earlier and more pronounced 
inflammatory response in ko animals as compared to wt. The low molecular weight 
proteins cyto- and chemokines influence a broad range of cellular functions and have 
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been mainly classified into pro- or anti-inflammatory cytokines. Once released, they 
rapidly and transiently bind to specific receptor molecules triggering a cellular 
response in a time- and tissue restricted manner (102). In the present study, the 
absence of aSMase and the overwhelming bacterial burden had an effect on cytokine 
release where levels of TNF-α and IL-6 peaked earlier in ko animals, only six hours 
following the septic insult. On the other hand, the increase in aSMase activity 
resulted in an increased expression of TNF-α and IL-6 in an in-vitro model of cellular 
stress response, but the cytokine response was abrogated in both pharmacological 
inhibition and knock-down models (103). 
The generation of ROS has been associated with ceramide-dependent TNF-α release 
(104), a fact that did not hinder ROS production by aSMase ko animals in the present 
study. This could however be explained by the 2-fold increase in levels of TNF-α 
measured in the latter animals which compensated for the impotence in rapid 
ceramide generation thus yielding a similar ROS release in the two genotypes during 
sepsis. Therefore, the hyperresponsive state in ko animals, triggering a pronounced 
cytokine release, also resulted in a significant increase in ROS production affecting 
the outcome. 
The cytokine storm was paralleled with an upregulation in transcripts, encoding for 
cyto- and chemokines, in circulating leukocytes of both wt and ko animals. Six hours 
following the septic insult, in ko animals, we found an increase in the expression of 
Tnfa transcripts in whole tissue homogenates of the liver reflecting the elevated 
levels of systemic TNF-α. However, the expression of Tnfa in lung tissue remained 
unchanged. A difference between the two organs was also observed in the analysis 
of the bacterial burden with the liver registering an overall higher bacterial burden. 
This in turn triggered a more pronounced inflammatory response by the liver which 
retains a crucial role in host response that, together with its larger organ mass, the 
overwhelming bacterial burden and the pronounced cytokines levels in blood, 
suggested a different response pattern during host response (105) explaining a 
variable pathway in the expression pattern in this organ. 
We also found a diminished expression of cathepsin G (Ctsg) in aSMase ko animals 
as compared to wt. Besides regulating phagocytosis, degranulation and ROS release, 
this serine protease has a role in the killing and digestion of engulfed microorganisms 
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(106, 107). Therefore, its diminished expression in our ko animals could have been a 
factor in the resulting overwhelming infection due to the hindered ability of 
leukocytes to eliminate phagocytised bacteria. 
Although the absence of aSMase in ko animals had adverse effects with respect to 
triggering a hyperresponsive state, it also presented with a possible protective role 
with respect to the altered expression of surface proteins (CD49d, CD62L and 
CD11b) and the associated absence in leukocyte activation. The wt animals on the 
other hand, presented with a leukocyte profile that is associated with an unfavorable 
outcome. Leukocyte activation and recruitment in the liver could trigger macro- and 
microcirculatory changes as well as leukocyte-endothelium interaction. An increase in 
hepatic leukocyte-endothelium interaction, through leukocyte rolling and sticking, 
leads to leukocytes sequestration and the development of hepatocellular damage 
through continuous local release of pro-inflammatory cytokines eventually resulting 
in hepatic dysfunction (87, 108, 109). The increase in aSMase activity in wt animals, 
followed by rapid generation of ceramide and lipid rafts, allows the recruitment of 
surface proteins such as CD11b (110). The expression of surface protein CD11b 
together with CD49d and CD62L are essential for the rolling and sticking 
phenomenon (111, 112) which was observed solely in wt animals. Due to the 
downregulation of CD49d and the missing upregulation in expression of CD11b and 
CD62L on circulating leukocytes of ko animals, no increase in leukocyte-endothelium 
interaction was observed.  
Changes in leukocyte-endothelium interaction were analyzed by intravital 
microscopy, a valuable investigative tool to elucidate changes in the liver during 
sepsis. However, it presents with challenges and limitations such as subjectivity in 
data analysis. This limitation was overcome by blinded analysis of the generated 
videos and images (no reference to the group) by two independent experienced 
scientists (Falk Gonnert and myself) thus limiting the subjectivity in the analysis 
process. Additionally, although Rhodamine 6G is the most commonly used dye in 
intravital microscopy (113), it presents with the limitation of being rapidly absorbed 
by the liver resulting in a bright background that is challenging with respect to data 
analysis. For this purpose, we chose to use CFDA-SE in the experimental setup as it 
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appeared to be more specific with respect to labeling of leukocytes thus presenting 
with clearer images. 
Comparing the two genotypes, a variety of measured parameters suggested a 
different pathway that however resulted in a similar, unfavorable outcome with only 
20% survival. The study of these two genotypes allowed us to elucidate a dual role 
of secreted aSMase in sepsis highlighting the crucial role this enzyme plays in the 
early phase of sepsis and the first line of defense against invading microorganisms. 
The abrogation of aSMase led to an overwhelming infection triggering a more 
pronounced inflammatory response and the progression of a generalized host 
response. On the other hand, an increase in activity with continuous ceramide 
generation appears to be detrimental in the late phase of host response as observed 
in wt animals. 
However, although the ko model presented with valuable scientific data, the loss of 
function model is limited with respect to transferability. The complete loss of function 
results in the development of Niemann-Pick disease which limits the usage of these 
animals to a maximum age of 10 weeks. As age is a factor known to affect the 
outcome in sepsis patients, with a more unfavorable outcome with older age, the use 
of older animals is of great value to address the role of aSMase with respect to age. 
However, this is not possible with the loss of function model. We can however 
overcome this limitation with the use of pharmacological inhibitors of aSMase which 
would allow us to bridge the gap between the experimental setup and the clinical 
situation. As pharmacological inhibition with desipramine could not result in the 
development of Niemann-Pick disease (61), older mice could be used for analysis of 
a possible variability with respect to outcome and is yet to be addressed but presents 
as an interesting perspective of the present study. In addition, due to its advantage 
with respect to translational research, desipramine is also a FDA approved drug that 
is already available and used to treat cases of clinical depression. This further 
encourages the elucidation of its possible benefits for the treatment of sepsis. 
However, for comparability reasons, we used young animals for pretreatment with 
desipramine similar to the loss of function model and wt littermates. 
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Additionally, with respect to enzyme activity, establishing and utilizing a heterozygote 
model is another interesting perspective in comparison with the established ko and 
pharmacological inhibition models. 
 
6. Pharmacological inhibition of the enzyme – Potential therapeutic use 
Since it became evident to us that aSMase is crucial in the early phase of host 
response, it is important to note that the use of pharmacological inhibitors such as 
desipramine does not result in a complete inhibition of the enzyme (61). Residual 
activity therefore prevents the development of the hyperresponsive state observed in 
ko animals and the alleviated levels of aSMase could protect against the detrimental 
effects of the enzyme in the late phase. Indeed, desipramine pretreatment alleviated 
the increase in aSMase secretion following PCI with significantly lower levels of 
aSMase activity in plasma as compared to wt following the septic insult. As such, 
aSMase activity in the leukocyte lysate remained significantly higher compared to 
vehicle. In fact, the increase in secreted aSMase (in plasma) has been associated 
with a consequent decrease in lysosomal aSMase (98). However, similar to the ko 
model, levels of ceramide were significantly higher at baseline (and following sepsis) 
as compared to vehicle-treated animals. Similar to other pharmacological inhibitors, 
desipramine functions as a non-specific inhibitor in the lysosomes. Therefore, it also 
deactivates other enzymes including the decreased expression of acid ceramidase 
that produces sphingosine-1-phosphate from ceramide. This could explain the higher 
levels of ceramide at baseline as well as following sepsis induction in this group as 
compared to vehicle (96, 114, 115). 
To investigate its possible beneficial role in the sepsis continuum, we measured a 
variety of parameters of host response following pretreatment with desipramine. We 
observed major differences between the inhibition group (wt animals pretreated with 
desipramine) and the vehicle wt animals that favor an overall better outcome. 
However, it is important to note that the present study focused on and addressed 
the effects of pretreatment with desipramine on sepsis which is not applicable to the 
clinical situation. Further experiments for the evaluation of the efficacy of 
desipramine when applied at the time point of sepsis induction as well as several 
days later is of great clinical value and is required to complete the scientific picture. 
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Unlike the complete loss of function model (85), desipramine pretreatment and the 
alleviated aSMase levels did not hinder the intracellular elimination process of 
bacteria by leukocytes. In fact, treatment of CF mice with pharmacological inhibitors 
appears to protect against Pseudomonas aeruginosa infections (65). Subsequent 
clinical trials have demonstrated a decrease in the incidence of upper respiratory 
tract infection and an improvement in overall lung function (116). Here we measured 
lower CFU in the liver and blood in the inhibition group as compared to vehicle 
without reaching significance. However, this was not unexpected as desipramine 
does not retain a short-term antibiotic effect. 
A distinct leukocyte phenotype in the inhibition group was also identified and 
associated with improved parameters of host response. An upregulation in the 
expression of Tnfa and Il6, together with higher baseline levels of ceramide, could 
explain the significantly increased levels of cytokines at the early phase of host 
response in the inhibition group. However, unlike the continuous increase observed 
in vehicle animals, systemic cytokine levels significantly dropped in the late phase of 
host response with abrogated levels of TNF-α (levels reaching baseline) that resulted 
in attenuated TNF-α dependent IL-6 release. These pharmacological inhibitors are 
known to have anti-inflammatory properties inhibiting LPS-mediated cytokine release 
by macrophages. In an endotoxemia shock model, pharmacological inhibition of 
aSMase also resulted in diminished TNF-α release and improved survival (61, 117). 
Following sepsis, a different expression profile of oxidative and stress-associated 
genes was also observed in desipramine pretreated animals and was associated with 
abrogated ROS production solely in these animals. Unlike ko animals, the high levels 
of TNF-α (measured in the inhibition group as well) did not compensate for the 
impotence in rapid ceramide generation (85). Desipramine pretreatment repressed 
the expression of Cyba and Ncf2, which were upregulated in both genotypes 
following the septic insult, thus abrogating ROS production. In fact, LPS-induced ROS 
production has been associated with an upregulation in Cyba, Ncf2 and Cybb 
(p22phox, p67phox, gp91phox) (118). Furthermore, treatment of human endothelial 
cells with desipramine also repressed TNF-α dependent ROS production (119).  
It is important to note however, that the qPCR experiments included only a low 
number of animals (two per group per time point). Although we could observe 
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significant differences, this only refers to biological significance. Due to the low 
number of animals, a statistical analysis of the differences between the groups was 
not performed. However, we could still observe clear differences in the fold change 
between the groups following the septic insult (as well as at baseline). 
Similar to ko animals, desipramine pretreatment also resulted in the downregulated 
expression of surface markers CD49d and CD62L on circulating leukocytes following 
sepsis induction. As previously discussed, these markers are crucial for the 
leukocytes’ rolling and sticking phenomenon which results in leukocyte sequestration 
and impairment of hepatic perfusion and microcirculation ultimately resulting in 
organ dysfunction (109, 120, 121). LPS-induced impairment in hepatic 
microperfusion has been reported following platelet-leukocyte and leukocyte-
endothelium interaction. Rolling and sticking leukocytes release cytotoxic mediators 
such as superoxide, arachidonic acid metabolites and proteases resulting in hypoxia 
(121). Desipramine pretreatment however resulted in the downregulation of these 
surface markers subsequently maintaining an unchanged number of rolling and 
sticking leukocytes following sepsis induction, a parameter that is promising with 
respect to outcome. 
Continuous platelet and leukocyte recruitment through rolling and sticking eventually 
results in the development of leucopenia and thrombocytopenia; hallmarks in sepsis 
development (121). Indeed, an increase in rolling and sticking in vehicle wt animals 
was reflected by a significant drop in leukocyte and platelet counts following the 
septic insult. Reports indicate that thrombocytopenia increases mortality in ICU 
sepsis patients where platelet activation and consumption contributes to the 
development of Disseminated Intravascular Coagulation (DIC) and could lead to the 
microvessel occlusion that is associated with the development of organ failure (122, 
123). Interestingly, following sepsis induction, both leukocyte and platelet counts 
remained stable in the inhibition group, also promising with respect to outcome. 
The overall effect of these altered parameters can be highlighted in the reflection on 
organ function and survival. Unlike vehicle-treated animals, markers of liver 
(dys)function and cholestasis (T-Bil and ALT) remained stable in the inhibition group 
following the septic insult. T-Bil significantly increased solely in the vehicle-treated 
animals six hours following the septic insult. Similarly, we measured significantly 
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higher levels of ALT in the vehicle-treated animals in early sepsis compared to 
inhibition. Another trend was observed in the levels of GGT which started to increase 
in early sepsis solely in vehicle treated animals without reaching significance.  
The summation of the effects of desipramine pretreatment reflected positively on 
organ function and more importantly on survival. Desipramine pretreated animals 
registered a 42% survival compared to 20% in both genotypes (wt and ko). 
Additionally, since desipramine is a non-specific inhibitor of aSMase, it could be 
argued that the more favorable outcome is unrelated to inhibition of aSMase but is 
rather a consequence of other effects brought on by the use of the inhibitor. For this 
purpose, we induced sepsis in ko animals pretreated with desipramine under the 
same conditions. Interestingly, this did not improve survival and these animals 
registered a rough 25% survival which proved that the improvement in outcome with 
the use of the inhibitor is in fact associated with inhibition of aSMase. However, it is 
still unclear whether the increase in aSMase activity is the course or the consequence 
with respect to tissue damage and the development of organ failure. 
Currently, treatment of sepsis comprises of established stratagems and uniform 
guidelines for supportive and complement therapy put forward by the health care 
societies such as the Surviving Sepsis Campaign (SSC) launched by different scientific 
societies to manage the disease (79, 124, 125). Some of these measures include 
regimens for antimicrobial therapy, adequate hemodynamic resuscitation and 
surgical drainage of infected fluid collections (79). Yet, an efficient treatment of the 
host response is still needed.  
During the course of clinical research in sepsis, various elements are critical and 
required during the investigation, several of which are fulfilled in the present study. 
These include the need for a well-established and standardized model, an efficient 
drug as well as patient data. Here, the use of FIASMAs (i.e. desipramine) in a 
clinically translation model of sepsis appears to be promising with respect to 
treatment and in improving survival through the inhibition of the aSMase enzyme 
which has been shown to increase in patients throughout the development of the 
disease (46, 126). Additionally, since FIASMAs are used in the ICU for the treatment 
of hospitalization-associated depression, our preliminary data through retrospective 
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data analysis revealed improvement in markers of organ (dys)function with the use 
of these drugs. 
 
IV- Conclusion 
The present study demonstrates a dual role of aSMase in host response. Although 
the enzyme is crucial in the early phase of host response with respect to the 
elimination of microorganisms, it is evident that its continuous increase has 
detrimental effects with poor outcome. The rise in the incidence of sepsis and the 
limited treatment options highlight the need for effective therapy. In the present 
study, the use of desipramine presents with promising results with respect to its 
possible therapeutic use in sepsis and further encourages clinical studies with the use 
of pharmacological inhibitors of aSMase in well defined septic patients. 
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V- Summary 
The increase in acid sphingomyelinase (aSMase) activity has been implicated in the 
severity of disease and its fatal outcome. In sepsis, aSMase activity has been shown 
to continuously increase throughout the continuum from SIRS (systemic 
inflammatory response syndrome) to severe sepsis. The inhibition of this enzyme 
with desipramine, a low molecular weight inhibitor, presents promising results in 
cystic fibrosis patients with improvement in lung function and patient status. We 
therefore addressed the question of whether secreted aSMase is involved in host 
response to infection, which is reflected in humoral and functional parameters of 
immune activation. We identified a dual function of this enzyme in host response 
where the activity of aSMase is essential during the early phase of host response 
with respect to bacterial elimination, yet the continuous increase in aSMase activity 
and ceramide generation presents with detrimental effects in the late phase of host 
response. We found a different cytokine profile between the genotypes (wt and ko) 
and yet more striking results following pharmacological inhibition with desipramine 
(i.e. Inhibition group). We observed a hyperresponsive state in the ko animals 
highlighted by an overwhelming bacterial burden and inflammatory response with 
poor outcome and presented with a 20% survival, similar to wt. We observed a more 
favorable overall profile in the inhibition group highlighted by abrogated and 
alleviated cytokine levels and ROS release associated with a repressed gene 
expression profile. Additionally, desipramine pretreatment resulted in the 
downregulation in expression of surface markers with subsequent unchanged values 
in numbers of rolling and sticking leukocytes. We also measured stability in markers 
of liver dysfunction in desipramine pretreated animals compared to the other two 
groups. In summation, the altered parameters reflected on survival with a more 
favorable survival of 42% in the inhibition group compared to a 20% survival in wt 
and ko animals. The use of the functional inhibitor desipramine reveals to be 
promising with respect to treatment of the host response. As it is already FDA 
approved for the treatment of several human conditions, the present study 
encourages further research into the use of desipramine for the treatment of host 
response. The presented data also encourage a clinical study with the use of 
desipramine in well defined sepsis patients. 
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Zusammenfassung 
Hintergrund und Fragestellung Sphingolipide fungieren neben ihrer vermeintlichen 
Hauptaufgabe als inerte Strukturkomponenten in Zellmembranen auch als hochaktive 
Metabolite und Mediatoren bei zahlreichen Stoffwechselprozessen wie zelluläre 
Stressantwort, Inflammation und Apoptose. Die Metabolite der Sphingomyelin-
hydrolyse, insbesondere Ceramid, einschließlich der Aktivität des Schrittmacher-
enzyms der raschen Ceramidbildung - die saure Sphingomyelinase, aSMase - sind bei 
Patienten in der Plasma-sezernierten Form mit Sepsis schweregradabhängig erhöht. 
Innerhalb der Zellmembran neigt Ceramid zur Selbstaggregation in Form von 
Makrodomänen, in welchen Rezeptorproteine zu funktionell aktiven Komplexen 
assemblieren und eine Vielzahl von Signalkaskaden (TNF-Rezeptor, CD95, TLR4 u.a.) 
in immunkompetenten Zellen verstärken. Die Sekretion der aSMase wird durch pro-
inflammatorische Zytokine stimuliert, andererseits vermindern funktionelle 
Inhibitoren des Enzyms wie Desipramin die Endotoxin-induzierte Zytokinfreisetzung 
in-vitro. Darüber hinaus verbesserte Desipramin in einer klinischen Studie bei 
cystischer Fibrose sowohl den pulmonalen Infektionsstatus (verbesserte Clearance P. 
aeruginosa) als auch Lungenfunktionsparameter. Vor diesem Hintergrund sollte eine 
mögliche Rolle des Enzyms und die Effekte einer Inhibition der aSMase bei der 
Wirtsantwort und bei der Entwicklung eines Organversagens untersucht werden. 
Methoden Nach Genehmigung wurden Mäuse einer polymikrobiellen Infektion mittels 
intraperitonelaer Applikation einer Stuhlsuspension unterzogen. Neben der 
Überlebensrate wurden die Enzymaktivität, die Ceramidbildbung in zirkulierenden 
Leukozyten, das Zytokinprofil, Bildung reaktiver Sauerstoffradikale, Organfunktions-
parameter, Phagozytose, Bakterienlast sowie zum einen mittels Intravitalmikroskopie 
die Leukozyten-Endothel-Interaktion, zum anderen mittels Durchflusszytometrie der 
Phänotyp der zirkulierenden Leukozyten analysiert. Dabei wurden folgende Versuchs-
gruppen verglichen: (i) Mäuse mit genetischer aSMase-Defizienz, (ii) deren wt-
littermates, sowie (iii) Mäuse nach pharmakologischer Inhibition der aSMase mit 
Desipramin. In Vorarbeiten wurde die Leukozyten-Endothel-Interaktion im 
(post)sinusoidalen Gefäßbett der Leber charakterisiert. 
Ergebnisse Nach Induktion der polymikrobiellen Sepsis entwickelten alle Tiere 
unabhängig von Genotyp oder Vorbehandlung das erwartete Krankheitsbild. 
Inhibition verhinderte den Sepsis-induzierten aSMase-Aktivitätsanstieg. Eine 
veränderte Wirtsantwort spiegelt sich in einer signifikant höheren Bakterienlast im 
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Blut und in Leberwebe genetisch defizienter Tiere wider, was mit einer signifikant 
erhöhten Phagozytoseleistung vergesellschaftet ist. Plasma-zirkulierende Zytokin-
konzentrationen erlaubten eine Gruppen-bezogene Differenzierung, dabei resultiert 
die pharmakologische Hemmung in einer veränderten Kinetik und Dynamik der 
Zytokinfreisetzung. Die Freisetzung reaktiver Sauerstoffradikale war bei 
pharmakologischer Inhibition vermindert und mit einem korrespondierenden Gen-
expressionsmuster in zirkulierenden Leukozyten assoziiert. Mittels intravitaler 
Mikroskopie wurden Unterschiede hinsichtlich der Leukozyten-Endothel-Interaktion in 
der Leber analysiert: Sechs Stunden nach Sepsisinduktion in wt-Tieren steigt der 
Anteil rollender Leukozyten von 6 auf 11/100 Leukozyten an, wobei in beiden 
Vergleichsgruppen bei ähnlichem Ausgangsniveau kein Anstieg zu verzeichnen ist. 
Ebenso steigt nur in wt die Anzahl adhärenter Leukozyten signifikant an. Ebenso fällt 
bei aSMase-Defizienz oder Inhibition die Expression des leukozytären 
Aktivierungsmarker CD49d signifikant vom Ausgangswert ab, was mit der 
verminderten endothelialen Adhärenz korrespondiert. Bei der Betrachtung von 
Parametern der Leberschädigung waren lediglich in den genetisch defizienten Tieren 
diese signifikant erhöht. In der Überlebensanalyse spiegelte sich die überschießende 
Wirtsantwort der ko-Tiere in einem früheren Versterben im Vergleich zur wt-Gruppe 
wider (jeweils 20%). Darüber hinaus war die Absterbekinetik in den Inhibitor-
behandelten Tieren verzögert und die Überlebensrate erhöht (42%).  
Interpretation Die Daten belegen eine wichtige Rolle der aSMase während der 
Wirtsreaktion bei polymikrobieller Infektion. Dabei kann dem Enzym möglicherweise 
eine duale, phasenabhängige Rolle zugeschrieben werden: In der frühen Phase ist 
ein Aktivitätsanstieg essentiell für adäquate Keimelimination und Stressantwort, 
wobei im loss-of-function Modell überraschenderweise eine Hyperreaktivität bei der 
Wirtsantwort auffällig ist. Bei pharmakologischer Inhibition scheint die Restaktivität 
(ca. 40% des Basalwerts) für die primäre Keimabwehr ausreichend, für die 
Hemmung der überschießenden Aktivität jedoch protektiv bezüglich der 
Stressantwort infektortferner Organe wirksam zu sein. Insgesamt erscheint die 
überschießende Wirtsantwort positiv beeinflusst. In Zusammenschau mit dem 
Zytokinprofil, dem verminderten Gewebeschaden, und dem resultierenden 
Überlebensvorteil sollte ein möglicher positiver Effekt der Inhibition mit einem in 
anderer Indikation zugelassenen Wirkstoff - wie beispielsweise Desipramin - 
zeitversetzt nach Infektion überprüft werden. 
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VI- Abbreviations 
 
ALT  alanine transaminase  
APC  Activated Protein C 
aSMase Acid Sphingomyelinase 
BW  Body Weight 
Cer  Ceramide 
CF  Cystic Fibrosis 
CFDA-SE Carboxyfluorescein diacetate succinimidyl ester 
CFU  Colony Forming Units 
CLP  Cecal Ligation and Puncture 
DAMPs Damage associated molecular patterns 
ES  Endothelium Surface 
FADD  FAS-associated death domain protein 
FDA  Food and Drug Administration 
FIASMAs Functional inhibitors of acid sphingomyelinase 
GGT  gamma glutamyl-transferase 
HMGB-1 High mobility group protein B1 
ICAM-1 Intracellular adhesion molecular-1 
ICU  Intensive Care Unit 
IL-1  Interleukin-1 
IL-6  Interleukin-6 
IL-10  Interleukin-10 
IL-17  Interleukin-17 
IP  Intra-peritoneal 
IRS-1  Insulin Receptor Substrate 1 
IVM  Intravital Microscopy 
ko   knock-out 
ko-Inh knock-out plus inhibition 
LPS  Lipopolysaccharide 
LS  Liver surface 
MFI  Mean Fluorescent Intensity 
MOF  Multiple Organ Failure 
PAMPs Pathogen associated molecular patterns 
PCI  Peritoneal Contamination and Infection 
PRR  Pathogen Recognition Receptors 
ROS  Reactive Oxygen Species 
SIRS  Systemic Inflammatory Response Syndrome 
Spp.  Species 
SSC  Surviving Sepsis Campaign 
T-Bil  Total Bilirubin 
TNF-α  Tumor Necrosis Factor-alpha 
TNFR  Tumor Necrosis Factor receptor 
UK  United Kingdom 
US  United States 
VCAM-1 Vascular Cell Adhesion Molecule-1 
wt  wild type 
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• Training in Adobe Photoshop 
• Training is Scientific presentations  
• Intravital Microscopy training supervised by Prof. Bauer and Dr. Gonnert 
• FELASA B: Animals Handling and Surgery 
• Summer school on Clinical Biophotonics 
• Workshop on Fungal Infections and Innate Immune Response 
• Additional expert training in Microbiology supervised by Prof. Rödel 
• Supervision of several projects of Bachelor, Master and Medical students 
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